TIL Therapy Shows Promise in Heavily Pretreated Metastatic Head and Neck Cancer: Phase 2 Trial Results
TIL therapy stabilized disease in 64% of metastatic head/neck cancer patients, extending survival to 9.5 months in heavily treated cases.
Head & Neck
Latest Posts
Versamune HPV Plus Pembrolizumab Doubles Survival in HPV16-Positive HNSCC: VERSATILE-002 Final Results
Versamune HPV plus pembrolizumab generated 39.3-month median OS vs 17.9 months historical benchmark in HPV16+...
FDA Approves Immune Checkpoint Inhibitor Drug for Patients With Resectable Locally Advanced Head and Neck Cancer
Pembrolizumab perioperatively extends survival in resectable locally advanced HNSCC with PD-L1 CPS ≥1 - first...